Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:10 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction
NCT02740699 · National Heart, Lung, and Blood Institute (NHLBI) · PHASE4 · terminated · last registry update 2024-10-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Principal Investigator resigned and closed program” | – | Registry record, National Heart, Lung, and Blood Institute (NHLBI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HMGCR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-16Results posted on the registry: Eli Lilly and Company, Rosuvastatin + Selpercatinib (NCT05906836)
- 2025-09-09Results posted on the registry: Organon and Co, Atozet 10/40 mg or 10/80 mg + Lipitor 40 mg or 80 mg (NCT05761444)
- 2025-08-22Results posted on the registry: University of Chicago, Atorvastatin (NCT02603328)
- 2025-07-16Results posted on the registry: Juan A. Arnaiz, Switch ritonavir-boosted PI + Continue Ritonavir-boosted PI+Rosuvastatin (NCT01935674)
- 2025-07-01Phase 3 first posted: Central South University, Atorvastatin + Metformin (NCT07045142)
- 2025-07-01Results posted on the registry: University College, London, Simvastatin (NCT03896217)
- 2025-06-10Phase 3 first posted: Aarhus University Hospital, acetylsalicyclic acid (ASA) + Clopidogrel (NCT07012629)
- 2025-05-29Results posted on the registry: Provident Clinical Research, Omacor + simvastatin (NCT00678743)
- 2025-05-23Results posted on the registry: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Cardiovascular Polypill + Treatment Prevention for Secondary CV (NCT02596126)
- 2025-05-16Phase 3 first posted: University of Colorado, Denver, Metformin + semaglutide (NCT06975111)
- 2025-05-15Phase 3 first posted: HealthBio, Inc., Maraviroc (MVC) + Atorvastatin, 10mg, 20mg, 40mg (NCT06974084)
- 2025-04-22Also stopped (withdrawn): ViiV Healthcare, Part A, C and D: VH3739937 500 mg + Part A: VH3739937 100 mg (NCT06533280)
- 2025-04-16Phase 3 first posted: Hospital do Coracao, Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin) + Colchicine 0.5 mg (NCT06930885)
- 2025-04-15Results posted on the registry: National Cancer Institute (NCI), Simvastatin (NCT02968810)
- 2025-04-15Results posted on the registry: University of Kansas Medical Center, Lipitor 20Mg Tablet + Lipitor 80Mg Tablet (NCT03360916)
- 2025-04-01Also stopped (withdrawn): Turning Point Therapeutics, Inc., TPX-0005 + Metformin Hydrochloride (NCT05828303)
- 2025-02-19Phase 3 first posted: AstraZeneca, Placebo + Rosuvastatin Dose 1 (NCT06834932)
- 2025-01-13Phase 3 first posted: CMG Pharmaceutical Co. Ltd, CMG190303(Dapagliflozin/Rosuvastatin) + Comparator 1: Dapagliflozin/Rosuvastatin placebo (NCT06772168)
- 2024-11-21Phase 3 first posted: Ain Shams University, Rosuvastatin 10 mg tablet. + Sertraline Pill (NCT06698666)
- 2024-11-20Phase 3 first posted: Xiang Luo, PCSK9 inhibitors combined with atorvastatin/rosuvastatin + Atorvastatin/Rosuvastatin (NCT06696820)
- 2024-10-17Phase 3 first posted: Hyundai Pharm, Ezetimibe/Rosuvastatin/Candesartan/Amlodipine + Candesartan/Amlodipine (NCT06646354)
- 2024-10-15Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Pitavastatin + Placebo (NCT02344290)
- 2024-08-19Phase 3 first posted: The George Institute, Atorvastatin (NCT06559072)
- 2024-08-02Results posted on the registry: Shionogi, MT-1186 + Rosuvastatin (NCT04481789)
- 2024-04-11Phase 3 first posted: Kafrelsheikh University, Atorvastatin 40 Mg Oral Tablet + Rosuvastatin 20mg (NCT06360120)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision